Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
(TBIO) Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
What are the next regulatory and commercialization milestones (e.g., Phase 3 initiation, FDA/EMA interactions) and their timing implications for long‑term shareholder value?
What are the key efficacy and safety endpoints reported, and how do they compare to existing therapies or competing pipeline candidates?
How will the Phase 2 TRANQUILITY trial results influence TBIO's valuation and near‑term stock price?
16 days ago